Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the
neoadjuvant setting: a case report.
- Catherine Percy,
- Schubert Thomas
, - Christine Galant,
- Thomas Kirchgesner,
- Filomena Mazzeo
Abstract
NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK
inhibitor larotrectinib is newly approved by the FDA. This paper reports
the first case of a man with a NTRK-rearranged soft tissue sarcoma
treated with larotrectinib in the neoadjuvant setting, in Belgium, to
avoid limb amputation.08 Oct 2020Submitted to Clinical Case Reports 13 Oct 2020Submission Checks Completed
13 Oct 2020Assigned to Editor
30 Oct 2020Reviewer(s) Assigned
15 Nov 2020Review(s) Completed, Editorial Evaluation Pending
16 Nov 2020Editorial Decision: Revise Minor
20 Nov 20201st Revision Received
21 Nov 2020Submission Checks Completed
21 Nov 2020Assigned to Editor
21 Nov 2020Review(s) Completed, Editorial Evaluation Pending
24 Nov 2020Editorial Decision: Accept
